Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.7523
+0.0583 (8.40%)
Apr 15, 2025, 4:00 PM EDT - Market closed
Prelude Therapeutics Stock Forecast
PRLD's stock price has decreased by -86.61% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Prelude Therapeutics stock have an average target of 4.50, with a low estimate of 4.00 and a high estimate of 5.00. The average target predicts an increase of 498.17% from the current stock price of 0.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prelude Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +564.63% | Apr 8, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $4 | Buy | Reiterates | $4 | +431.70% | Mar 12, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $7 → $4 | Buy | Reiterates | $7 → $4 | +431.70% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +564.63% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +564.63% | Oct 28, 2024 |
Financial Forecast
Revenue This Year
n/a
from 7.00M
Revenue Next Year
n/a
EPS This Year
-1.49
from -1.68
EPS Next Year
-1.08
from -1.49
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.09 | -0.45 | -0.30 | ||
| Avg | -1.49 | -1.08 | -0.94 | ||
| Low | -1.85 | -1.65 | -1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.